HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 3 (2006), Issue 9 (September)

1. In vitro replication capacity of HIV-2 variants from long-term aviremic individuals.
   Virology, 353(1): 144-54. [Abstract] [Full-text]
2. Specific interaction of CXCR4 with CD4 and CD8alpha: functional analysis of the CD4/CXCR4 interaction in the context of HIV-1 envelope glycoprotein-mediated membrane fusion.
   Virology, 353(1): 52-67. [Abstract] [Full-text]
3. Characterization of TRIM5alpha trimerization and its contribution to human immunodeficiency virus capsid binding.
   Virology, 353(1): 234-46. [Abstract] [Full-text]
4. Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V.
   Virology, 353(1): 184-92. [Abstract] [Full-text]
5. Human immunodeficiency virus type 1 nucleocapsid zinc-finger mutations cause defects in reverse transcription and integration.
   Virology, 353(1): 41-51. [Abstract] [Full-text]
6. Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites.
   Expert Opin Drug Deliv, 3(5): 613-28. [Abstract] [Full-text]
7. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.
   Pediatrics, 118(3): e711-8. [Abstract] [Full-text]
8. HIV-1-infected and/or immune activated macrophages regulate astrocyte SDF-1 production through IL-1beta.
   Glia, 54(6): 619-29. [Abstract] [Full-text]
9. Brief report: assessing adherence to pediatric antiretroviral regimens using the 24-hour recall interview.
   J Pediatr Psychol, 31(9): 989-94. [Abstract] [Full-text]
10. Hugging my uncle: the impact of a parent training on children's comfort interacting with persons living with HIV.
    J Pediatr Psychol, 31(9): 891-904. [Abstract] [Full-text]
11. Community collaborative youth-focused HIV/AIDS prevention in South Africa and Trinidad: preliminary findings.
    J Pediatr Psychol, 31(9): 905-16. [Abstract] [Full-text]
12. Predictors of engagement and retention into a parent-centered, ecodevelopmental HIV preventive intervention for Hispanic adolescents and their families.
    J Pediatr Psychol, 31(9): 874-90. [Abstract] [Full-text]
13. The impact of drug use on perceptions of credibility in indigenous outreach workers.
    Qual Health Res, 16(8): 1108-19. [Abstract] [Full-text]
14. Diagnosis of HIV infection in pregnancy: data from a national cohort of pregnant women with HIV in Italy.
    Epidemiol Infect, 134(5): 1120-7. [Abstract] [Full-text]
15. Opposing roles of blood myeloid and plasmacytoid dendritic cells in HIV-1 infection of T cells: transmission facilitation versus replication inhibition.
    Blood, 108(6): 1957-64. [Abstract] [Full-text]
16. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia.
    J Infect Dis, 194(7): 926-30. [Abstract] [Full-text]
17. HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria.
    J Infect Dis, 194(7): 917-25. [Abstract] [Full-text]
18. Repeated intravaginal inoculation with cell-associated simian immunodeficiency virus results in persistent infection of nonhuman primates.
    J Infect Dis, 194(7): 912-6. [Abstract] [Full-text]
19. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges.
    J Infect Dis, 194(7): 904-11. [Abstract] [Full-text]
20. Systemic treatment of AIDS-related Kaposi sarcoma: current status and perspectives.
    Cancer Treat Rev, 32(6): 445-55. [Abstract] [Full-text]
21. HIV-1-induced pulmonary oxidative and nitrosative stress: exacerbated response to endotoxin administration in HIV-1 transgenic mouse model.
    Am J Physiol Lung Cell Mol Physiol, 291(4): L811-9. [Abstract] [Full-text]
22. Mutation of the Rev-binding loop in the human immunodeficiency virus 1 leader causes a replication defect characterized by altered RNA trafficking and packaging.
    J Gen Virol, 87: 3039-44. [Abstract] [Full-text]
23. Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment.
    J Antimicrob Chemother, 58(4): 714-22. [Abstract] [Full-text]
24. No vaccine against HIV yet--are we not perfectly equipped?
    Virol J, 3: 60. [Abstract] [Full-text]
25. Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire.
    N Engl J Med, 355(11): 1141-53. [Abstract] [Full-text]
26. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons.
    J Viral Hepat, 13(10): 683-9. [Abstract] [Full-text]
27. Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life.
    J Viral Hepat, 13(10): 678-82. [Abstract] [Full-text]
28. Human T-cell lymphotropic virus type 3: complete nucleotide sequence and characterization of the human tax3 protein.
    J Virol, 80(19): 9876-88. [Abstract] [Full-text]
29. Major histocompatibility complex class II molecules promote human immunodeficiency virus type 1 assembly and budding to late endosomal/multivesicular body compartments.
    J Virol, 80(19): 9789-97. [Abstract] [Full-text]
30. Induction of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses in HIV vaccine trial participants who subsequently acquire HIV-1 infection.
    J Virol, 80(19): 9779-88. [Abstract] [Full-text]
31. Complementation of human immunodeficiency virus type 1 replication by intracellular selection of Escherichia coli formula supplied in trans.
    J Virol, 80(19): 9641-50. [Abstract] [Full-text]
32. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity.
    J Virol, 80(19): 9586-98. [Abstract] [Full-text]
33. Selection on the human immunodeficiency virus type 1 proteome following primary infection.
    J Virol, 80(19): 9519-29. [Abstract] [Full-text]
34. Revealing domain structure through linker-scanning analysis of the murine leukemia virus (MuLV) RNase H and MuLV and human immunodeficiency virus type 1 integrase proteins.
    J Virol, 80(19): 9497-510. [Abstract] [Full-text]
35. Human ESCRT-II complex and its role in human immunodeficiency virus type 1 release.
    J Virol, 80(19): 9465-80. [Abstract] [Full-text]
36. Glutamate metabolism in HIV-infected macrophages: implications for the CNS.
    Am J Physiol Cell Physiol, 291(4): C618-26. [Abstract] [Full-text]
37. Bioinformatics-assisted anti-HIV therapy.
    Nat Rev Microbiol, 4(10): 790-7. [Abstract] [Full-text]
38. Predictors of early death in a cohort of Ethiopian patients treated with HAART.
    BMC Infect Dis, 6: 136. [Abstract] [Full-text]
39. Preparing peer educators for teen HIV/AIDS prevention.
    J Pediatr Nurs, 21(5): 378-84. [Abstract] [Full-text]
40. Body composition and metabolic effects of a diet and exercise weight loss regimen on obese, HIV-infected women.
    Metabolism, 55(10): 1327-36. [Abstract] [Full-text]
41. Factors associated with HIV infection in adolescent females in Zimbabwe.
    J Adolesc Health, 39(4): 596.e11-8. [Abstract] [Full-text]
42. Alteration of cytochrome oxidase subunit I labeling is associated with severe mitochondriopathy in NRTI-related hepatotoxicity in HIV patients.
    Mod Pathol, 19(10): 1277-88. [Abstract] [Full-text]
43. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.
    Nature, 443(7109): 350-4. [Abstract] [Full-text]
44. The health care relationship (HCR) trust scale: development and psychometric evaluation.
    Res Nurs Health, 29(5): 477-88. [Abstract] [Full-text]
45. High incidence of genotypic variance between sequential herpes simplex virus type 2 isolates from HIV-1-seropositive patients with recurrent genital herpes.
    J Infect Dis, 194(8): 1115-8. [Abstract] [Full-text]
46. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression.
    J Infect Dis, 194(8): 1108-14. [Abstract] [Full-text]
47. Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study.
    J Infect Dis, 194(8): 1098-107. [Abstract] [Full-text]
48. Effect of perinatal antiretroviral drug exposure on hematologic values in HIV-uninfected children: An analysis of the women and infants transmission study.
    J Infect Dis, 194(8): 1089-97. [Abstract] [Full-text]
49. Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma.
    J Infect Dis, 194(8): 1078-88. [Abstract] [Full-text]
50. Therapy Insight: CNS manifestations of HIV-associated immune reconstitution inflammatory syndrome.
    Nat Clin Pract Neurol, 2(10): 557-65. [Abstract] [Full-text]
51. Quantitative four-dimensional tracking of cytoplasmic and nuclear HIV-1 complexes.
    Nat Methods, 3(10): 817-24. [Abstract] [Full-text]
52. The central DNA flap of the human immunodeficiency virus type 1 is important for viral replication.
    Biochem Biophys Res Commun, 349(3): 1100-10. [Abstract] [Full-text]
53. The uncertain significance of anti-glomerular basement membrane antibody among HIV-infected persons with kidney disease.
    Am J Kidney Dis, 48(4): e55-9. [Abstract] [Full-text]
54. Young age is a risk factor for HIV among female sex workers--an experience from India.
    J Infect, 53(4): 255-9. [Abstract] [Full-text]
55. Syncytial giant cell hepatitis in human immunodeficiency virus-infected patients with chronic hepatitis C: 2 cases and review of the literature.
    Hum Pathol, 37(10): 1344-9. [Abstract] [Full-text]
56. Protease inhibitor-associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA5-1131T->C gene variation.
    Clin Chem, 52(10): 1914-9. [Abstract] [Full-text]
57. HIV-specific CD8 T cells express low levels of IL-7Ralpha: implications for HIV-specific T cell memory.
    Virology, 353(2): 366-73. [Abstract] [Full-text]
58. Inhibition of endogenous reverse transcription of human and nonhuman primate lentiviruses: potential for development of lentivirucides.
    Virology, 353(2): 482-90. [Abstract] [Full-text]
59. HIV-1 transgenic rat CD4+ T cells develop decreased CD28 responsiveness and suboptimal Lck tyrosine dephosphorylation following activation.
    Virology, 353(2): 357-65. [Abstract] [Full-text]
60. HPTN 024 study: histologic chorioamnionitis, antibiotics and adverse infant outcomes in a predominantly HIV-1-infected African population.
    Am J Obstet Gynecol, 195(4): 1065-74. [Abstract] [Full-text]
61. Clinical and economic outcomes of nonadherence to highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Med Care, 44(10): 893-9. [Abstract] [Full-text]
62. Human immunodeficiency virus-positive patient with bilateral corneal endothelial deposits.
    Optometry, 77(10): 494-8. [Abstract] [Full-text]
63. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection.
    JAMA, 296(12): 1498-506. [Abstract] [Full-text]
64. Antiretroviral therapy and HIV prevention in India: modeling costs and consequences of policy options.
    Sex Transm Dis, 33(10): S145-52. [Abstract] [Full-text]
65. Finding patients eligible for antiretroviral therapy using TB services as entry point for HIV treatment.
    Trop Med Int Health, 11(10): 1567-75. [Abstract] [Full-text]
66. Normalisation of cerebrospinal fluid biomarkers parallels improvement of neurological symptoms following HAART in HIV dementia--case report.
    BMC Infect Dis, 6: 141. [Abstract] [Full-text]
67. The cost-effectiveness of expanding harm reduction activities for injecting drug users in Odessa, Ukraine.
    Sex Transm Dis, 33(10): S89-102. [Abstract] [Full-text]
68. From trial intervention to scale-up: costs of an adolescent sexual health program in Mwanza, Tanzania.
    Sex Transm Dis, 33(10): S133-9. [Abstract] [Full-text]
69. Men who have sex with men and women: a unique risk group for HIV transmission on North Carolina College campuses.
    Sex Transm Dis, 33(10): 585-93. [Abstract] [Full-text]
70. Correlates of syphilis seroreactivity among pregnant women: the HIVNET 024 Trial in Malawi, Tanzania, and Zambia.
    Sex Transm Dis, 33(10): 604-9. [Abstract] [Full-text]
71. Whole-body proteolysis rate is elevated in HIV-associated insulin resistance.
    Diabetes, 55(10): 2849-55. [Abstract] [Full-text]
72. Nuclear import defect of human immunodeficiency virus type 1 DNA flap mutants is not dependent on the viral strain or target cell type.
    J Virol, 80(20): 10262-9. [Abstract] [Full-text]
73. Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy.
    J Virol, 80(20): 10229-36. [Abstract] [Full-text]
74. Infection of CD127+ (interleukin-7 receptor+) CD4+ cells and overexpression of CTLA-4 are linked to loss of antigen-specific CD4 T cells during primary human immunodeficiency virus type 1 infection.
    J Virol, 80(20): 10162-72. [Abstract] [Full-text]
75. Immune response in rhesus macaques after mixed modality immunisations with DNA, recombinant adenovirus and recombinant gp120 from human immunodeficiency virus type 1.
    APMIS, 114(10): 690-9. [Abstract] [Full-text]
76. Lessons for management of sexually transmitted infection treatment programs as part of HIV/AIDS prevention strategies.
    Am J Public Health, 96(10): 1760-1. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.